Achilles Therapeutics Plc - ADR logo

ACHL

Achilles Therapeutics Plc - ADR

$3.27

Earnings Summary

Revenue
$0Mn
Net Profits
$-17.36Mn
Net Profit Margins
-Inf%
PE Ratio
0.55

Highlights

Revenue:

Achilles Therapeutics Plc - ADR’s revenue jumped NaN% since last year same period to $0Mn in the Q1 2022. On a quarterly growth basis, Achilles Therapeutics Plc - ADR has generated NaN% jump in its revenue since last 3-months.

Net Profits:

Achilles Therapeutics Plc - ADR’s net profit fell -26.08% since last year same period to $-17.36Mn in the Q1 2022. On a quarterly growth basis, Achilles Therapeutics Plc - ADR has generated 4.8% jump in its net profits since last 3-months.

Net Profit Margins:

Achilles Therapeutics Plc - ADR’s net profit margin jumped NaN% since last year same period to -Inf% in the Q1 2022. On a quarterly growth basis, Achilles Therapeutics Plc - ADR has generated NaN% jump in its net profit margins since last 3-months.

PE Ratio:

Achilles Therapeutics Plc - ADR’s price-to-earnings ratio after this Q1 2022 earnings stands at 0.55.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Achilles Therapeutics Plc - ADR post its latest quarter earnings

EPS Estimate Current Quarter
-0.56
EPS Estimate Current Year
-0.56

Highlights

EPS Estimate Current Quarter:

Achilles Therapeutics Plc - ADR’s earning per share (EPS) estimates for the current quarter stand at -0.56 - a -12% fall from last quarter’s estimates.

EPS Estimate Current Year:

Achilles Therapeutics Plc - ADR’s earning per share (EPS) estimates for the current year stand at -0.56.

Key Ratios

Key ratios of the Achilles Therapeutics Plc - ADR post its Q1 2022 earnings

Earning Per Share (EPS)
-0.45
Return on Assets (ROA)
-0.15
Return on Equity (ROE)
-0.24
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Achilles Therapeutics Plc - ADR’s earning per share (EPS) jumped 94.63% since last year same period to -0.45 in the Q1 2022. This indicates that the Achilles Therapeutics Plc - ADR has generated 94.63% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Achilles Therapeutics Plc - ADR’s return on assets (ROA) stands at -0.15.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Achilles Therapeutics Plc - ADR’s return on equity (ROE) stands at -0.24.

Dividend Per Share (DPS):

Achilles Therapeutics Plc - ADR declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-03-31
-0.5
-0.45
10%

Company Information

Achilles is a clinical-stage biopharmaceutical company developing precision T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. The Company has two ongoing Phase I/IIa trials, the CHIRON trial in patients with advanced non-small cell lung cancer (NSCLC) and the THETIS trial in patients with recurrent or metastatic melanoma. Achilles uses DNA sequencing data from each patient, together with its proprietary PELEUS™ bioinformatics platform, to identify clonal neoantigens specific to that patient, and then develop precision T cell-based product candidates specifically targeting those clonal neoantigens.

Organisation
Achilles Therapeutics Plc - ADR
Headquarters
245 Hammersmith Road, London, United Kingdom
Employees
2.02K